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Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Present treatments 
for CVD rely heavily on surgical interventions and drug therapies that relieve symptoms rather 
than cure the disease. Therefore, there is active research to find alternative therapeutic 
approaches for CVD. The small gene regulating molecules, microRNAs (miRNAs) are known 
to mediate structural changes in cardiovascular diseases. Therapy using miRNAs is a novel 
approach to restoring function of damaged cardiac tissue in CVD. Global tissue expression of 
miRNAs is regulated via movement of miRNAs through multiple vesicular transport pathways 
and gap junctions. Connexin 43 (Cx43) which is the protein constituting the gap junctions 
specifically between ventricular cardiomyocytes, may provide a potential therapeutic target for 
regulating the expression of miRNAs in cardiac tissue. The aim of this study was to explore 
miRNA transport via human Cx43 in a single cell model and then in human cardiomyocytes. I 
hypothesised that Cx43 will have a role in intercellular miRNA transport and will thus mediate 
miRNA expression in cardiac cells. 
 
To characterise the function of Cx43 in miRNA transport, without interference from vesicular 
transport pathways seen in cardiomyocytes, a single cell model of human-Cx43 mRNA injected 
Xenopus laevis oocytes was constructed. The function of exogenously expressed human Cx43 
was determined using in vitro electrophysiology. No significant increase in current was 
observed in connexin activating Ca2+ free solution for the human-Cx43 mRNA injected oocytes 
(n=6, N=3)1 in comparison to the control non-Cx43 expressing oocytes (n=6, N=3). However, 
consistent with the previous studies, current across the cell membrane of all oocytes from both 
groups was reduced by 100% or 50% on re-application of Ca2+ (2 mM) or non-specific connexin 
blocker, lanthanum (0.05 mM), respectively. The Ca2+ and lanthanum sensitivity confirms that 
the observed current is mediated by connexins. Western blot analysis on the native oocyte 
suggests the presence of endogenous connexin, which could be contributing to the lack of 
significant functional difference for the human cRNA injected oocyte. Hence, an endogenous 
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connexin knockdown model of oocytes must be considered for testing the permeability of Cx43 
to miRNA. 
 
The possibility of transport in adult human cardiomyocytes was tested using AC16 cells derived 
from human ventricular cardiomyocytes. The transport of transfected miRNA-1 from the cells 
into its extracellular environment (cell media) was tested using lanthanum (2 mM). No 
significant difference in miRNA transport was seen upon blocking connexin transport by 
lanthanum (n=3).  
 
The findings in this thesis represent a first step towards a better understanding of the possibility 
that miRNA moves through gap junctions in adult human cardiomyocytes.  
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Cardiovascular diseases (CVDs) are the disorders of the heart and blood vessels. Under such 
pathological conditions, the cardiac tissue, mainly the myocardium is damaged and drastically 
remodelled. These structural changes in the cardiac tissue reduce elasticity of the heart and thus 
impairs the blood pumping function of the organ (Cohn, 1995). As postnatal cardiac tissue is 
known to have limited regenerative abilities, structural changes in CVD are therefore 
permanent. In recent years, advances in CVD treatments have been made, however CVD still 
remains to be the leading causes of mortality and morbidity worldwide (World Health 
Organization, 2018). Approximately 17 million pre-mature deaths (>70 years old) per year are 
caused by CVDs (World Health Organization, 2018) making CVD an ongoing problem for the 
health of the global population and a major burden for the healthcare systems. 
 
It is now known that the structural changes in cardiac tissue are preceded by molecular changes 
occurring in cardiac cells (Lin et al., 2009). The role of small non-coding RNA molecules, 
known as microRNAs (miRNAs) in CVD has been brought to light and they are now being 
researched extensively as potential molecular targets in CVD therapy (Thum et al., 2007). 
Presently, transport pathways of miRNAs are being investigated in multiple in vivo mouse 
models to restore lost function of cardiac tissue (Van Rooij et al., 2006; Kosaka et al., 2010). 
However, the known current miRNA transport pathways lack specificity and hence this reduces 
the efficiency of miRNA-mediated treatment (Zhu et al., 2012; Ottaviani et al., 2018). This 
thesis thus investigates a potential new transport pathway for miRNAs between cardiomyocytes 




1.1 CVD Pathology 
CVDs essentially encompass all the diseases caused by dysfunction of the cardiac tissue and 
blood vessel. These include left ventricular hypertrophy (increase in cell size), myocardial 
infarction (apoptotic loss of cardiomyocytes), arrhythmia (abnormal beating of the heart), and 
heart failure. In all these cardiac pathologies, the myocardial tissue is damaged which results in 
poor cardiac function. The cardiac output (amount of blood leaving the heart per minute) and 
stroke volume (cardiac output per heartbeat) are thus decreased due to reduced contractility of 
the heart muscle (Jackson, 2000). In order to maintain homeostasis and meet the oxygen 
demand of peripheral organs, the heart undergoes further structural changes such as cardiac 
hypertrophy to compensate for impaired function of the myocardium (Jackson, 2000). These 
structural changes are however only beneficial in the short term. Chronically, thickening of the 
heart muscle caused by hypertrophy, restricts blood flow to the myocardium and this 
predisposes to myocardial infarction and ischemia, which causes further cardiomyocyte death 
and dysfunction (Cohn, 1995). There is also increased apoptosis of the cardiomyocytes which 
are replaced by other non-contractile cells such as fibroblast and as a result, fibrosis occurs. 
Thus, there is subsequent weakening of the heart wall (Diwan et al., 2007). These overall 
changes in the structure of the myocardium, interfere with the conductivity across the chambers 
of the heart; especially fibrosis which can lead to arrhythmia (Tomaselli & Marban, 1999). 
Therefore, though a specific CVD can occur initially, it can progress to other CVDs initiating 
a vicious cycle with progressive reduction in function of the heart and eventual heart failure 
(Conrad et al., 1995; Tomaselli & Marban, 1999; Jackson, 2000). To stop the progression of 
disease to heart failure, it is vital to identify the new ways to restore function to the damaged 
myocardium. 
1.2 CVD Treatments 
The loss of cardiac tissue function in the diseased heart can currently be treated surgically, by 
implantation of battery-operated pacemakers, coronary arterial stents, and coronary artery 
bypass grafts. These methods work best to slow the progression of CVDs, but do not stop future 
 3 
occurrence of CVD incidents (Epstein et al., 2008; Mulpuru et al., 2017). Exercising and taking 
cholesterol-lowering drugs or beta blockers prescribed by doctors, reduce workload of the heart 
and risk of CVD but are only capable of slowing rather than stopping the progression of the 
disease (Greenland et al., 2001). Therefore, in all cases CVD patients are still prone to heart 
failure. Heart transplantation can restore cardiac function in end stage heart failure, but heart 
transplant treatment is limited by the availability of donors and relies heavily on recipient-donor 
matching and this is not always possible (Lund et al., 2017). Hence, at present the major 
research focus for CVD treatment has shifted towards molecular therapy. Researchers are now 
focusing on gene regulatory molecules that modulate structural changes in the cardiovascular 
tissue with the intention of targeting these molecules in future CVD research to restore function 
of the diseased myocardium (Paiva & Agbulut, 2017; Ottaviani et al., 2018). 
 
1.3 miRNAs as molecular targets 
miRNAs are a class of tissue specific small (22 nucleotide) single stranded non-coding RNA 
molecules (Chen et al., 2006). They regulate gene expression at post-transcriptional level and 
thus regulate cellular pathways that mediate pathophysiological events in the cells (Bartel, 
2004). They form part of the RNA-induced silencing complex (RISC) and interact with target 
messenger RNA (mRNA) strand to negatively regulate gene expression (Filipowicz et al., 
2008). Furthermore, miRNAs can be transported between cells which enables miRNAs to 
extend their effect on the overall tissue (Kosaka et al., 2010; Boon & Vickers, 2013). They have 
evolutionary conserved sequences and target multiple cellular pathways (Bartel, 2004). 
miRNAs are hence an ideal molecular target for controlling pathophysiological events in the 
tissue, at cellular level. 
 
1.3.1 miRNA biogenesis 
A primary microRNA (pri-miRNA) strand is transcribed by RNA polymerase II from miRNA 
genes or from introns of protein coding genes in the nucleus of the cell. The endonuclease 
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enzymes Dorsha and the cofactors DiGoerge syndrome critical region gene 8 (DGCR8) cleave 
pri-microRNA to form ~70 nucleotide long precursor miRNA (pre-miRNA) strand which is 
transported from the nucleus of the cell and into the cytoplasm via exportin proteins (Han et 
al., 2004). When in the cytoplasm, pre-miRNA is cleaved by Dicer enzyme to form a functional 
22 nucleotide long miRNA strand that is of ~1nm diameter in its linear form; this strand is also 
referred to as mature miRNA (Grishok et al., 2001) (Figure 1.1). 
 
1.3.2 miRNAs mode of action 
miRNAs carry out their gene regulatory function in the cytoplasm of the cell. When 
incorporated into RISC, mature miRNAs interact with the 3’untranslated region (UTR) of 
multiple mRNA strands. The degree of complementation between these two strands determines 
the silenced fate of the proteins encoded by the miRNA-complementing mRNA strand. A 
perfect complementation between the two strands results in miRNA mediated degradation of 
the mRNA whereas a partial complementation results in translation repression of mRNA 
(Filipowicz et al., 2008) (Figure 1.1). This flexibility in complementation enables one miRNA 
to regulate expression of multiple proteins and thus regulate various gene regulatory pathways 





Figure 1.1 miRNA synthesis and mode of action. A precursor miRNA (pre -miRNA) strand 
is transcribed in the nucleus of the cell and is later processed into mature miRNA in the 
cytoplasm. It is the mature miRNA strand that form part of RISC and interacts with mRNA 
strand to regulate protein expression. [Image adapted from (Ryan et al., 2015)]. 
 
1.3.3 miRNA in cardiovascular development 
There are 526 miRNAs in the human heart (Lewis et al., 2003). These miRNAs collaboratively 
dictate fundamental cellular biological processes within cardiac tissue, such as proliferation, 
differentiation, apoptosis and conductivity and are therefore extensively involved in 
cardiogenesis (Zhao et al., 2007). To list a few, miRNA-1 and miRNA-23 tightly control the 
expression of mRNA coding for anti-hypertrophic Muscle-specific RING-finger protein 
whereas miRNA 24 regulates apoptotic protein Bim coding mRNA, to maintain structural 
homeostasis of the cardiac tissue (Zhao et al., 2005; Lin et al., 2009; Qian et al., 2011). 
miRNA-1 which is the predominantly expressed miRNA in cardiomyocytes, interacts with 
potassium ion channel Kir2.1 and calcium ion channel regulating molecule B56-alpha to 
regulate conductivity across the heart (Yang et al., 2007). Of the other cardiac miRNAs, 
miRNA-16 mediates vascular development and miRNA-133 allows differentiation of cardiac 
stem cells into myogenesis. miRNAs are thus vital for development of the heart and for 




1.3.4 miRNAs and CVD 
Dysregulated expression of miRNAs in cardiac cells is correlated with the onset and 
development of pathology in cardiac tissue. miRNA-1, miRNA-133, miRNA-208 and 63 other 
miRNAs are reported to be dysregulated in the failed human heart (Thum et al., 2007). In 
infarcted myocardium, there is downregulation of miRNA 24, miRNA-1 and miRNA-133 
(Boštjančič et al., 2010; Qian et al., 2011). Downregulation of miRNA-1 is also associated with 
hypertrophy and ventricular tachyarrhythmia (Curcio et al., 2013). Contrastingly, independent 
overexpression of miRNA-1 and miRNA-23 are also known to induce cardiac hypertrophy 
(Van Rooij et al., 2006; Lin et al., 2009). Myocardial dilation, on the other hand, is linked with 
downregulated expression of miRNA-24 which has been shown to increase apoptosis in murine 
cardiomyocytes (Qian et al., 2011). Dysregulated expression of miRNAs in cardiomyocytes 
thus plays a crucial role in modulating CVDs. 
 
Interestingly, restoration of downregulated miRNA expression with miRNA mimics (synthetic 
RNA duplexes with similar sequence to mature miRNAs) has been shown to restore function 
of the cardiac cells, especially cardiomyocytes (Vicencio et al., 2015). The in vivo 
administration of miRNA mimic in CVD mouse models led to significant reduction in infarct 
size, in hypertrophy and in cell apoptosis in cardiac tissue (Qian et al., 2011; Curcio et al., 
2013). Use of miRNA to recover from CVDs is evidently promising. However, post miRNA 
administration side-affects such as tumour vascularisation have also been reported (Zhu et al., 
2012) (Gray et al., 2015). 
1.3.5 Challenges with miRNA-based therapy for CVD treatment 
As form of a molecular treatment, the miRNA mimics were delivered through the current 
known miRNA transport route of membrane bound vesicles (Zhu et al., 2012; Gray et al., 2015; 
Zhang et al., 2016). Details of miRNA transport pathways are described in section 1.3. Here, 
for the miRNA-based treatment, miRNA mimics were packaged in vesicles which were injected 
intravenously to reach the cardiac cells via circulation. It was intended that the vesicles would 
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be taken up by the cardiac cells to restore expression of the dysregulated miRNAs and 
subsequently improve cardiac function. However, as the miRNA packaged vesicles were 
administered in the systemic circulation this led to the non-specific uptake of administered 
miRNA mimics. Hence, off-target effects were observed in the non-cardiac tissue due to 
disturbance of homeostasis of cells in these tissues. 
 
Therefore, the administration of miRNA mimics is though promising for restoring function of 
the diseased heart, it is also evident that an improved method of miRNA administration is 
required to increase miRNA uptake specificity in the cardiac tissue. To improve delivery, it is 
vital to understand the transport pathways miRNA use to migrate between cells and induce their 
effect on the overall tissue. 
1.4 miRNA transport pathways 
miRNA transport between cells are considered vital for cell to cell communication. miRNAs 
are transported as signalling molecules to maintain synchronicity in the activity of the cells and 
thus allow the organ to function as a whole (Kosaka et al., 2010; Vicencio et al., 2015; Ottaviani 
et al., 2018). Understanding the transportation mechanism for these miRNAs is hence of 
importance in order to add to the knowledge of factors contributing to the dysregulated miRNA 
expression in a cardiomyocyte which, as previously discovered, initiates cardiac pathology. 
Further, a deeper understanding of the miRNA transport route would potentially aid in 
developing a more specific form of miRNA administration in miRNA-based therapy. Current 
known miRNA transport routes are via membrane bound vesicles (i.e. exosomes and 
microvesicles) that travel through extracellular fluid (ECF). Recent literature (discussed in 
section 1.4.4) provides some evidence for transport of miRNAs through connexin proteins that 




1.4.1 Membrane bound vesicle: Exosomes 
Exosomes are small (30-100nm) vesicles formed by the inward budding of late endosome and 
are collectively enveloped within multivesicular bodies (MVB) (Figure 1.2). Alongside 
proteins, lipids and mRNA, miRNAs are selectively loaded in exosomes in ceremide dependent 
manner (Kosaka et al., 2010; Wang et al., 2014). The release of exosomes from donor cells and 
their uptake in recipient cell, both occur via receptor-ligand mediated interaction involving the 
cell surface marker, SNAREs (Soluble N-ethylmaleimide-sensitive-fusion-protein attachment-
protein-receptor). The v-SNARE (vesicle SNARE) on the surface of MVB interacts with t-
SNARE (target SNARE) located on the plasma membrane of the recipient cells and initiates 
fusion of MVB with the plasma membrane of the cell (Fader et al., 2009). Exosomes are thus 
released in the ECF and are then endocytosed by neighbouring cells or more distant cells. Once 
in recipient cells, miRNAs from exosome are released in the cytoplasm (Figure 1.2). The 
miRNAs then bind to the RISC of the recipient cell and interact with mRNA to alter protein 
expression and thus physiology of the cell (Wang et al., 2014). 
 
However, the exosomal transport of miRNA is subject to limitation induced by the ECF. The 
rate of release of vesicle and the distance travelled in the ECF to reach the recipient cells are 
rate limiting steps in the exosomal transport route. Additionally, cell surface markers on all 
exosomes are similar; regardless of the cell types exosomes are derived from (Kosaka et al., 
2010). Lack of variation in surface makers of vesicles thus reduces the specificity of miRNA 
transport. 
 
1.4.2 Membrane bound vesicle: microvesicles 
Microvesicles are comparatively larger in size (110-4000nm) than exosomes. They are created 
by outward budding and blebbing of the surface plasma membrane of the cell and are released 
into the ECF (Figure 1.2). Similar to exosomes, microvesicles travel in plasma and carry 
signalling molecule including miRNAs, to facilitate communication between cells (Hunter et 
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al., 2008). The miRNAs brought in by microvesicles also interact with RISC in the recipient 
cells and modulate gene expression (Cantaluppi et al., 2012; Diehl et al., 2012). As the miRNAs 
transported in microvesicles also follow the ECF transport route, they are subjected to similar 
rate limiting steps as exosomes and hence microvesicles also lack specificity and efficiency in 








Figure 1.2 Transport routes/mechanisms of miRNAs from donor cell to the recipient cell 
between cardiomyocytes. Once the miRNAs are transported from the nucleus and into the 
cytoplasm of the cells, they can go in either of the following four different directions. 1) 
Incorporated in RISC to interact with the target mRNA strand. 2) miRNA can be packaged into 
exosomes via endosomal pathways and be released in extracellular fluid (ECF) to be taken up 
by recipient cells. 3) Accumulation of miRNA on the cytoplasmic surface of the plasma 
membrane may results in budding body and transport of miRNA in microvesicles through ECF 
route. 4) Lastly, miRNAs from the cytoplasm of one cell can be transported across the adjacent 
cells via gap junctional protein connexin, although this remains to be confirmed in human 
cardiomyocytes (refer to section 1.4.4). Once the transported miRNAs are taken up in the 
cytoplasm of recipient cell through exosomes, microvesicels or via gap junctions, they can 






















1.4.4 Connexin mediated miRNA transport 
1.4.4.1 Connexin protein 
Connexins are a class of transmembrane protein. They have four hydrophobic membrane-
spanning domains, two extracellular domains and three cytoplasmic domains which includes 
the C-terminus and N-terminus end of the protein (Willecke et al., 2002) (Figure 1.3). 
Hexamers of connexin proteins are assembled in the endoplasmic reticulum or in the Golgi 
organ of the cell, and then travel to the plasma membrane where they exist as hemichannels. In 
the plasma membrane of the two adjacent cells, connexin protein hexamers form subunits of 
gap junctions which are vital for communication between cells (Figure 1.3). It has been long 
been known that connexin formed gap junctions (pore size of 1.0-1.5nm) provide a pathway for 
movement of small molecules, ions and gene regulating molecules between adjacent cells 
(Goodenough et al., 1996; Söhl & Willecke, 2004). Hence, connexins play a crucial role in 
synchronizing activity between cells thereby maintaining tissue homeostasis and contributing 
to physiological function of the organ. 
 
As with miRNAs, connexins are also expressed in a tissue specific manner. The gap junctions 
between ventricular cardiomyocytes are predominantly formed by Cx43 (Vozzi et al., 1999). 
The connexin channel is opened by acidic pH and lack of Ca2+ (Morley et al., 1996; Trexler et 
al., 1999). The permeability of the channel is therefore pH and Ca2+ sensitive.  Its carboxyl 




Figure 1.3 Structure of gap junctions. A) molecular structure of a single connexin protein 
where M1, M2, M3 and M4 represent the transmembrane domains of the protein. E1 and E2 
represent the extracellular loops whereas NH2 and COOH represent N-terminus and C-
terminus ends respectively. B) A schematic diagram of hemichannels formed by connexin 
hexamers and the formation of gap junctions by hemichannels of the adjacent cells. Green arrow 
through gap junction represent the passage through which small gene regulatory molecules and 
ions can move between cells. [self-made figure]. 
 
1.4.4.2 Evidence of connexin mediated miRNA transport 
There is seminal evidence to demonstrate the connexin mediated transport of miRNAs. Using 
HeLa cell line, Zong et al., (2016) were the first to demonstrate the permeability of mouse 
connexin (Cx43, Cx31, Cx30 and Cx26) to miRNA-96 and miRNA-183 which are miRNAs 
abundantly expressed in the inner ear. Further, they showed that fluorescent tagged miRNA 
mimics (fluro-miRNA-mimic) were able to be transported from the transfected cells into non-
transfected cells following co-culturing of the two cell groups. This was associated with gene 
silencing in the recipient non-transfected cells. In contrast, when connexin in the mimic 
transfected cells was blocked, the genes in the recipient non-transfected cells were not silenced. 
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Connexin thus mediated miRNAs transport between cells and the transported miRNA retained 
their function and were able to regulate gene expression in the recipient cell. Similar findings 
of connexin mediated miRNA transport have been reported by (Lemcke et al., 2017) in isolated 
neonatal cardiomyocytes. In their experiemnt, a 50% decresease of miRNA mimic transport 
was observed following Cx43 kockdown. 
 
The accumulated evidence from studies by Zong et al., (2016); Lemcke et al., (2017), for 
connexin mediated miRNA transport potray connexin as one of the major transport routes for 
miRNA. As the molecules move through the gap junctions between adjacent cells, they pass 
directly from the cytoplasm of one cell to another. Therefore, the movement of gene regulating 
molecule, miRNA, from donor cell to recipient via connexin formed gap junctions avoid any 
limitations enforced by passage through the ECF. Here, Cx43 mediated miRNA transport is 
targeted specifically to the adjacent recipient cell and the effects are potentially more precise 
and circumscribed in comparison to miRNA delivery by membrane bound vesicles. 
 
While it has been shown that connexin is permeable to miRNAs in neonatal mouse 
cardiomyocytes through mouse isoform of Cx43, it is not known if this is true for adult human 
cardiomyocytes. Given the tissue specific characteristic of miRNAs and Cx43, it is important 
to establish whether or not connexin can provide a pathway for cell to cell movement of 
miRNAs. If so, this would open up the possibility of targeting cell-specific communication in 




Aims and objectives 
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Aim: To test if human Cx43 will mediate transport of miRNAs in adult human 
cardiomyocytes. 
This aim will be tested in two stages. First, permeability of human Cx43 to miRNA will be 
tested in a single cell model. Human Cx43 will be expressed in Xenopus laevis oocytes, as their 
relatively big size (~1mm) allows for easier manipulation. Additionally, Xenopus oocytes in 
the in vitro setting do not release membrane bound vesicles. Thus, characterisation of Cx43 
mediated miRNA transport in the single cell model of Xenopus oocytes, eliminates the 
possibility of interference from vesicular transport of miRNAs. Second, to test if miRNA can 
pass through Cx43 in human cardiomyocytes, the aim will be tested in AC16 cardiomyocytes 
– a cell line derived from the ventricles of the adult human heart. 
 
Objectives: 
1. To test the permeability of human Cx43 to miRNAs in a single cell model of 
Xenopus oocytes 




As the pore size of the Cx43 formed gap junction (~1.5nm) conforms with the diameter of linear 
miRNA molecules (1.0nm), I hypothesise that Cx43 will mediate transport of miRNAs in both 






2.1 Xenopus laevis oocytes 
Use of Xenopus laevis for this project was approved by the Environmental Protection Authority, 
and harvesting of oocytes was approved by the University of Otago Animal Ethics committee. 
 
2.1.1 Xenopus laevis housing 
The female Xenopus laevis frogs were housed in Tecniplast XenoPlus Stand Alone system. 
This system consists of 12 tanks each designed to hold 17 litres of water and facilitate up to 
four frogs. The pH and conductivity of the tank water was regulated and monitored by the 
XenoPlus system. Approximately 10% of the tank water was discharged every day and was 
replaced with fresh water from rain water tank. The tank had various filters (biological, 
mechanical and carbon) along with UV disinfectant light to minimise microbial growth and 
thus ensure flow of good quality water. Each frog had a designated tank and individual frogs 
were distinguished from one another by their unique skin pattern which was photographed and 
archived. 
 
2.1.2 Harvesting Oocytes: 
Oocyte harvest was performed surgically. Because the surgical procedure requires former 
experience, the oocyte harvest was mainly performed by Dr. Jan-Peter Baldin and PhD student 
Sama Mugloo while I observed and learned the technique under their supervision. First, the 
frog was anesthetised by transferring it into a container with water and Tricaine methane 
sulfonate (1.3 g/L, pH 7) (Aldrich, Cat. No. E10521-50G) for 15 minutes. To confirm surgical 
level of anaesthesia, lack of response to painful stimuli was tested by pinching the rear foot of 
the frog with forceps. The animal was then transferred to a surgical bench and laid on its back 
on top of a paper towel that was pre-soaked in anesthetising solution. Wet paper towels were 
used to cover the thorax and lower limbs of the frog and only the abdomen was exposed for the 
surgery. Povidone-iodine prep pads (Dynarex, Cat No. 1108) were used to sterilise the surgical 
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sight. Using autoclaved scissors, a ~1cm vertical incision was made through the epidermal layer 
of the lateral abdomen, just above the groin. A second incision was made through the fascia 
and muscle layer to access the ovarian lobes. The ovarian lobes were externalised using blunt 
forceps to gain access to the oocytes. The lobes were cut and placed into a 50mL falcon tube 
filled with culture oocyte Ringers solution (CulOri) (see Table 5 in appendix for solution 
components) and the surgical incision on frog was closed in two steps with different needles. 
First, the incision through the muscle layer was closed by uninterrupted suture using 
monofilament (B. BRAUN, Cat No. 2021-02-09). Then, using a different suture (DemeTECH, 
Cat No. PGA184019F4P), the incision through the epidermal layer was closed in the similar 
manner. As part of recovery, post-surgery the frog was moved into a clean water tank and 
sporadically monitored for 24 hours before being transferred back to its designated tank.  
 
The maximum number of oocyte harvests from each animal was four and all surgeries were 
recorded in the animal register. To reduce stress to the animal, each surgery was performed at 
least 3 months apart. For the fourth harvest, the frog was sacrificed via spinal puncture, and 
oocytes were then harvested. 
 
2.1.3 Oocyte isolation 
Extracted ovarian lobes were transferred into a 5 x 5 cm petri dish filled with culOri buffer. 
Using forceps, the oocytes were torn from the ovarian lobes. They were then enzymatically 
defolliculated at room temperature by 90 minutes incubation in collagenase enzyme (1.5mg/ml) 
(Serva, Cat. No. 17465.02) dissolved in culOri. This was followed by three washes in Ca2+ free 
oocyte Ringers (Ca2+ free Ori) to deactivate collagenase and in the last Ca2+ free Ori wash, 
oocytes were incubated on a rocker (Select BioProducts, platform rocker Rock-it) for 15 
minutes. A final wash of oocytes with culOri was done. The healthiest stage V-VI oocytes were 
selected under the dissection microscope and placed in a conical 96 well plate with one oocyte 
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per well bathed in 200µl of culOri. The 96 well plates containing the oocytes were stored in the 
incubator at 17oC to be used in experiments later. 
 
2.1.4 Endogenous connexin expression in Xenopus oocytes 
Before expressing human Cx43 for testing miRNA transport, the expression of connexin coding 
genes in native Xenopus oocytes was quantified. Xenopus oocytes are known to express Cx38 
(Ebihara, 1996) and thus expression of Cx38 gene was used as reference. RNA was extracted 
from oocytes and gene reverse-transcription – quantitative polymerase chain reaction (RT-
qPCR) was then performed to quantify the expression of Xenopus Cx43 genes relative to 
Xenopus Cx38 genes. Human Cx43 gene was targeted as the negative control and 18S was used 
as the endogenous control for normalising RT-PCR results. 
 
2.1.4.1 RNA extraction 
All the procedures using TRIzol were carried out in the fume hood. In a 1.5ml microcentrifuge 
tube, three oocytes from the same frog alongside three 1.6mm stainless steel beads were added 
in total of 500 µl of TRIzol reagent. The oocytes were homogenised in bullet blender for 2 
minutes at the speed of 8. The tubes were visually inspected for satisfactory homogenisation. 
Homogenised samples were then centrifuged at 15000g for 15 minutes in 4oC to pellet the 
debris at the bottom of the tubes. The resulting supernatant was transferred into a new 1.5 ml 
microcentrifuge tube. Complete dissociation of nucleoprotein complexes in the supernatant was 
ensured by incubating the samples at room temperature for 5 minutes. 
 
Next, chloroform was added in 1:0.2 ratio of TRIzol : Chloroform and the sample was vortexed 
for 15 seconds. These samples were incubated at room temperature for 3 minutes and then 
centrifuged at 12,000g at 4oC for 15 minutes. The top colourless aqueous phase containing 
RNA was transferred into a new 1.5 ml microcentrifuge tube. To obtain high purity RNA from 
the samples, extra care was taken to avoide contact with the organic interphase material during 
aqueous phase collection. 
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Later, to form an RNA pellet, 100% isopropanol was added to the aqueous phase at a ratio of 
1:0.5 of Trizol : Isopropanol. This was followed by a 10 minute incubation at room temperature 
and then centrifuge step of 12,000g for 10 minutes at 4oC. The supernatant was discarded, and 
the pellet was washed in 75% ethanol at a 1:1 ratio of Trizol : ethanol. The samples were 
vortexed for 15 seconds and then centrifuged at 7500g for 5 minutes in 4oC. The supernatant 
was discarded, and the RNA pellet was air dried at room temperature for 10 minutes. The RNA 
pellet was resuspended in 40 µL of nuclease free water and incubated in heating block at 60oC 
for 15mins. Lastly, RNA concentration was measured using the nanodrop reader. Purity ratio 
of RNA was defined by 260/280 (i.e. RNA to protein) and 260/230 (RNA/phenol) and was 
recorded along with the RNA concentration (ng/µl) of the samples. RNA samples were then 
stored at -80oC or were immediately processed for reverse transcription. 
 
2.1.4.2 Gene RT-PCR 
Reverse Transcription 
The RNA samples were reverse transcribed to form the complimentary DNA (cDNA) strand as 
cDNA is known to be chemically more stable than RNA. Reverse transcription (RT) was 
performed according to the supplier’s protocol (High Capacity cDNA Reverse Transcription 
Kit, appliedbiosystems by Thermo Fisher Scientific., Lithuana; Cat. No. 00568522). To be able 
to use 18S as the reference gene for normalisation in real-time PCR, random primers were used 
to generate a cDNA library. As random primers are capable of annealing at multiple points 
along the RNA script, they can therefore produce a large cDNA yield. 
 
In thermal cycling tubes, 20 µl of RT master mix was prepared per RNA sample with 10X RT 
buffer, 25X deoxyribonucleotide triphosphate (dNTP) mix (100mM), 10X RT Random Primers 
and MultiScribe Reverse Transcriptase (PrimeScriptTM RT Reagent Kit, Takara Bio., Japan). 
The volumes of individual RT master mix forming components are listed in Table 1. Then 2000 
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ng of RNA from each sample was added to the RT master mix. The total volume of RNA 
sample with RT master mix was made up to 40 µl for each sample with nuclease free H2O. 
These reaction mixtures were placed in the thermocycler and run at 25oC for 10 minutes, then 
at 37oC for 120 minutes to generate cDNA, and lastly at 85oC for 5 minutes to inactivate reverse 
transcriptase enzyme via heat. 
 
Table 1. Per reaction volume for components forming RT mater mix. ‘X’ stands for ‘times’. 
 
component Volume for 1 Reaction (µL) 
10X RT Buffer 4.0 
25X dNTP Mix (100mM) 1.6 
10X RT Random Primers 4.0 
MultiScribe Reverse Transcriptase 2.0 
Nucleases-free H2O 8.4 
Total volume 20 
 
Polymerase Chain Reaction 
Cycle threshold (Ministry of Health; National Minimum Data Set et al.) values obtained from 
qPCR were used as a quantitative measure of connexin genes expression in native oocytes. For 
each gene target, PCR master mix was made up of 5 µl of 2X Syber Premix Ex Taq, 0.2 µl 50X 
ROX dye, 3.4 µl RNAse free H2O and 2 µl of each forward (10 µM), and reverse primers (10 
µM) of the gene of interest (see appendix 4 for primer details). In a 96 well plate, 9 µl of PCR 
master mix was added with 1µl of cDNA template. Each sample for each gene was run in 
triplicate. The plate was sealed and to ensure mixture of all components, the plate was briefly 
spun down. The 96 well plate was then inserted in the StepOne Plus real time PCR machine 
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and was run for 1 cycle of 30 seconds at 95oC to activate the enzyme, followed by 40 cycles of 
5 seconds at 95oC and lastly, 1 cycle of 30 seconds at 60oC. 
 
2.1.4 Expressing human Cx43 in Xenopus oocytes 
The pTNTTM vector consisting of human Cx43 nucleotide sequence (GenScript., U2946C1120-
3) was used. First, the pTNTTM vector was amplified to gain high yield of human Cx43 DNA. 
This was followed by in vitro transcription to synthesise cRNA from the amplified DNA and 
the cRNA was injected into Xenopus laevis oocytes using the robot ‘roboocyte’ to allow for 
human Cx43 expression. 
 
2.1.4.1 The pTNTTM vector 
The pTNTTM vector was chosen as the vector for human Cx43 sequence because it contains 
SP6 and T7 polymerase promoters which allows for efficient in vitro synthesis of RNA (figure 
2.1). This vector also contains 5’ b-globin leader and synthetic poly(A)30 tail and these have 
been reported to enhance protein expression (Wakiyama et al., 1997). Ampicillin resistance 
gene was present in the vector as a selection marker. 
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Figure 2.1 pTNTTM vector circle map. A vector of human Cx43 used to generate cRNA that 
was injected into oocytes. The plasmid was purchased from GenScript. OHu25686C represents 
insertion of human Cx43 DNA sequence. [self-made figure]. 
 
2.14.2 DNA amplification by bacterial transformation 
To produce sufficient amount of plasmid with human Cx43 DNA for the reverse transcription 
to produce cRNA for Xenopus oocyte expression system, E. coli strain DH5a competent cells 
(Cat. No. 18265-017) were used as the transient host for subcloning the plasmid vector. The 
100 µl of DH5a cells were mixed with 10 µl of DNA and incubated on ice for 30 minutes. This 
sample was heat shocked by 45 seconds incubation at 42°C for transforming the plasmid into 
the DH5a cells and then samples were put back on ice for 2 minutes. The 950 µl of lysogeny 
broth (LB) was then added to the sample and it was subsequently incubated on shaker at 220g 
for 1 hour at 37°C. Following incubation, the samples were centrifuged at 10,000g for 1 minute 
and the resulting supernatant was discarded. Cells were resuspended in 300 µl of LB medium, 
of which 100 µl was plated on agar plate containing 100 µg/ml ampicillin (Applichem, Cat. No. 
A0839,0025) to selectively grow the plasmid transfected DH5a cells. The agar plates were 
incubated for 16 hours at 37°C and a single colony was selected the next day to be transferred 
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into 500 ml LB medium with 75 µg/ml of ampicillin. This was incubated on the shaker at 
220rpm for 16 hours at 37°C and then the steps of plasmid isolation from the bacteria were 
carried out. 
 
2.1.4.3 Plasmid isolation 
The NucleoBand® Xtra plasmid purification kit (Clonetech, Cat. No. 740410.10) was used and 
the plasmid DNA purification was carried out using the manufacturer’s ‘midipreparation’ 
protocol. In brief, 100 ml of bacterial culture was harvested from the previously made 500 ml 
stock in LB medium, by 15 minutes centrifugation at 5000g at 4°C.  Collected cells were 
resuspended in 8 ml of RES (resuspension) buffer and were then lysed by subsequent 
application of 8 ml of LYS (lysis) buffer. Cell lysis was then neutralised by adding 12 ml of 
NEU (neutralisation) buffer to the reaction. The lysate was then loaded on to the column filters 
provided by the manufacturer and the flow-through (driven by gravity) was discarded. Filters 
were washed using 5 ml of Buffer EQU and discarded. The leftover column was washed with 
8 ml of Buffer WASH. Plasmid DNA was then eluted with the application of 5 ml of Buffer 
ELU. Eluted plasmid DNA was purified by precipitation. The 3.5 ml of 100% isoproponal was 
added to the elute plasmid DNA, vortexed and centrifuged at 15,000g for 30 minutes at 4°C 
and the supernatant was discarded. The DNA pellet obtained was washed with 70% ethanol (2 
ml) and centrifuged again at 5000g for 5 min at room temperature. Ethanol was removed, and 
the pellet was air-dried for ~5 minutes. Lastly, the pellet was dissolved in RNase free water and 
stored at -20°C. 
 
2.1.4.4 Plasmid DNA linearisation 
To be able to convert plasmid DNA into cRNA, the pTNTTM vector consisting of Cx43 DNA 
had to be linearised. As the vector contained BamHI cleaving site, the corresponding restriction 
enzyme (Roche, Ca. no. 10567604001) was used. The 1 µg of DNA was mixed with 1 µl of 
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restriction enzyme (BamHI) and 10x reaction buffer, and was incubated for 90 minutes at 37°C. 
The enzymatic reaction was inactivated by additional incubation at 65°C for 15 minutes. 
 
2.1.4.5 In vitro transcription 
In order to transcribe DNA into cRNA, SP6 mMessage mMachine Kit (Ambion, Cat. No. 
AM1340) was used to perform in-vitro transcription. The procedure was carried out according 
to the supplier’s manual. Components of this reaction consisted of 2x NTP/CAP, 10x reaction 
buffer and enzyme mix SP6 and were mixed in the ratio of 1 : 0.2 : 2 respectively. To this, 1 
µg of linear DNA template was added, and the total volume of reaction was brought up to 20 
µl with nuclease-free water. The reaction was incubated for 2 hours at 37°C. TURBO DNase 
(1 µl) was then added to the reaction and this mixture was incubated at 37°C for 15 minutes. 
MEGAclearTM Kit (Ambion, Cat. No. AM1908) was used in accordance to the supplier’s 
manual to purify RNA. First, 350 µl of Binding Solution was added to the 100 μl of cRNA, 
followed by addition of 250µl of 100% ethanol. The reaction was loaded onto column filters 
and centrifuged for 1 minute at 10,000g. Flow-through was discarded and 500 μl of Wash 
Solution was added. The centrifuge step of 1 minute at 10,000g was repeated. The filter was 
then transferred into a new Eppendorf tube and 50 μl of pre-heated (95 °C) Elution Solution 
was then added to the filter and centrifuged again at 10,000g for 1 minute to collect cRNA. The 
yield (ng/µl) and 260/280 purity ratio of cRNA was measured using nanodrop reader. Finally, 
the cRNA sample was stored at -80°C. 
 
2.1.4.6 cRNA microinjections into oocytes: 
The human Cx43 cRNA microinjection into oocytes was done using the roboinject robot (Multi 
Channel Systems, Germany). The 96 well plate containing oocytes sorted previously was used. 
In the 96 well plate, each oocyte was placed in an individual well filled with 200 µl of culOri 
and the plate was placed on the robot platform. A injection pipette (IN-25, Multi Channel 
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Systems, Germany) was filled with mineral oil to prevent RNA dilution was aligned to pierce 
the centre of the oocyte. The robot injector was set at the fluid ejection speed of 30nl/second. 
To express human Cx43, the oocytes were injected with 15 ng of the purified cRNA. These 
were labelled as Cx43 oocytes. For the control group, equivalent amount of nuclease-free water 
was injected into the native oocytes. The oocytes were stored in an incubator at 18°C for 24 
hours to allow protein expression. 
 
2.1.4.7 Solution suitability test 
As a precautionary step to prevent oocyte death in the electrophysiology experiment from 
oocytes failing to survive in the types of solutions used, the survival of oocytes was tested in 
Cx43 activating Ca2+ free Ori solution and Cx43 blocking lanthanum (La3+) solutions.  La3+ is 
toxic to the cells, therefore to determine the La3+ concentration for optimal oocyte survival, 
oocytes were incubated with 50 μM, 100 μM, 500 μM and 1000 μM of La3+ prepared in Ca2+ 
free Ori. Oocytes bathed in culOri were used as positive control as Xenopus laevis oocytes 
sustain their structure and function in culOri for at least ~5 days. Oocytes bathed in simply 
dH2O (distilled water) were used as the negative control. To ensure, difference in survival of 
oocyte across solution is not affected by varying osmolarity between solutions, the osmolarity 
of all solution was adjusted to 193 mOsmols/l by the addition of mannitol and detailed 
components of each solutions are listed in appendix 1, table 5. Oocytes were randomly assigned 
to the solution groups in a 96 well plate where each well consisted of one oocyte with 200 μl 
of the assigned solution. Survival was determined by counting the number of dead oocytes 
under a light microscope for each solution at zero hour, 24hour, 48hour, 72hour and 96hour 
time points. Only oocytes like the one displayed in image A of figure 2.2 were considered to be 




Figure 2.2 Pictures of Xenopus laevis oocytes. Image A shows a healthy oocyte whereas 
image B, C and D are dead oocytes. Red circles represent leakage of cytoplasm due to 
deterioration of the cell membrane. These images were used as a reference to document viability 
of cells in different solutions. All images are taken from 20x lens under a dissection light 
microscope.  
  
2.1.5 Connexin 43 expression analysis 
The functionality of Cx43 in WT oocytes and in native oocytes (control) was tested using 
current recordings measured using the two-electrode voltage clamp (TEVC) technique. TEVC 
is a wel established technique used in characterising properties of the exogenously expressed 
proteins in Xenopus laevis oocytes (Wagner et al., 2000; Guan et al., 2013). Ca2+ free Ori was 
used to activate connexin specific current across the oocyte and culOri was used to deactivate 
the current. Additionally, the effect of connexin blocker Lanthanum (La3+) was also tested to 
confirm the presence of Cx43 mediated current. These solutions were introduced to oocytes in 
the flow chamber through a pressure regulated perfusion system. 
 
2.1.5.1 TEVC systems set-up 
Initially, the flow chamber was filled with culORi and with the help of Pasteur pipette, oocyte 
was positioned on the concentric circular dent of the chamber (Figure 2.3). To set up flow, 
solutions in channels 1 to 3 of the perfusion reservoir were filled as follow: culOri, Ca2+ free, 
and 50 µM La3+ dissolved in Ca2+ free solution. Pressure in the system was adjusted to 3.5 psi 
to mediate flow through the reservoir and flow of each solution into the recording chamber was 
controlled by switching on and off button for their respective channel. 
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The system was then set up to measure whole cell current. A voltage electrode to measure 
membrane potential and a current electrode were constructed with glass capillary tubes 
(Hilgenberg, Cat. No. 1103237). These were filled with 18 µl of 3 mM potassium chloride 
(KCl) for conductance and bleach coated silver wires were inserted to form microelectrodes. 
The TURBO TEC-05 TEVC amplifier (NPI, Tamm, Germany) was used to record information 
from both electrodes. Only the electrodes with resistance between 2-4W were considered 
suitable for the experiment. After submerging the electrodes in culOri, the amplifier was used 
to adjust the offsets for both current and voltage electrodes. Using a micromanipulator, 
electrodes were then gently advanced through the oocyte membrane into the cell. 
 
The reference electrodes, which were also made of bleached silver wires, were placed in the 
recording chamber at throughout the experiement. The oocyte was voltage clamped at a 
membrane potential of -60mV and transmembrane current recorded by amplifier was displayed 





Figure 2.3 Diagrammatic representation of TEVC set up for measuring whole cell current 
of Cx43 expressing and control oocytes. [Image adapted from Daniel Barth (2017, 
unpublished)].  
 
2.1.5.2 TEVC recording Protocol 
The whole cell currents for both Cx43 expressing and control oocytes were recorded using the 
same protocol. First, the oocyte activity was measured without any solution flow for 30 seconds. 
Then flow of culOri was turned on for 1 minute followed by flow of Ca2+ free Ori for 3 minutes. 
The oocyte was then washed with culOri for 2 minute and 50 µM La3+ solution was then 
introduced for 3 minutes. Lastly, the current across the oocyte was brought to baseline with 
culOri and the recording was stopped. 
2.2 AC16 Cardiomyocytes 
The AC16 cell line is a commercial cell line derived from adult human ventricular 
cardiomyocytes fused with fibroblasts to sustain their growth in an in vitro setting. Use of AC16 
cell line is becoming common for characterising molecular changes that occur during 
pathophysiological events in the cardiac cells (Palomer et al., 2008; Palomer et al., 2015; Ram 
et al., 2017). (Davidson et al., 2005) has shown that AC16 cells retain the nuclear and 
mitochondrial DNA of the primary cardiomyocytes. As an inherent trait of ventricular 
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cardiomyocytes, AC16 cells endogenously express Cx43 in their plasma membrane. The gap 
junctions between these cells have been shown previously shown to be functional in the in vitro 
setting (Davidson et al., 2005). Hence, AC16 cells were used in this project to test the concept 
of Cx43 mediated miRNA transport in cardiomyocytes. 
 
2.2.1 Culturing of AC16 cells 
AC16 cells for the treatment protocol, were first grown in T75 flasks to ~80% confluency. 
Advanced Dulbecco's Modified Eagle Medium/F-12 (DMEM/F-12, Thermo Fisher Scientific, 
US) with Fetal Bovine Serum (FBS, at 10%) and antibiotic antimitotic (A/A, at 1%) was added 
to make up an aliquot of complete DMEM/F-12. The complete DMEM/F-12 media was 
warmed to 37°C and 8 ml was added to the culture, which was enough to cover the surface of 
one T75 flask. The flasks were then transferred to the incubator set at 37°C, 5% CO2 and 95% 
relative humidity. Cell media was changed every 24 hour and the cells were grown to the 
confluency of ~80%. The confluency percent of the cells were determined by inspection under 
a light microscope. 
 
2.2.2 Cell maintenance 
Upon reaching ~80% confluency, the cells were passaged in a 1:3 ratio. The growth media, 
complete DMEM/F-12, was aspirated out and the cells were washed with phosphate buffer 
saline (PBS) solution at 37 oC to remove debris. The trypsinisation agent, TrypLE (2.5 ml) was 
added to the T75 flask and incubated for 30-50 seconds at room temperature to allow 
disassociation of the cells from the surface of the flask. Then 8 ml of complete DMEM/F-12 
media was added to saturate the trypsin and the cell suspension was collected in a 15 ml falcon 
tube. To recover cells in the form of a pellet, the cell suspension was centrifuged at 3000g for 
5 minutes. The resulting supernatant was aspirated out and cell pellet was resuspended in 3 ml 
of fresh complete DMEM/F-12 media. Cell counting was then done using haemocytometer 
(Life technologies, USA). Here, 100 µl of the cell suspension was used to create a 1:5 dilution 
 29 
and the diluted sample was combined with Trypan Blue dye in a 1:1 ratio. The 10 µl of the 
trypan blue dyed cells was placed on haemocytometer slide and was used to attain proportion 
of the live cells to dead cells. The live cell count was used to calculate the volume of cells 
required to seed a specific cell density. 
 
2.2.3 Experiment design 
To test if Cx43 mediates transport of miRNAs, transport of miRNA-1 was specifically tested 
as it is the predominantly expressed miRNA in the heart and it is highly involved in regulating 
pathophysiological events in the cardiomyocytes. The presence of U6 and miRNA-16 was also 
detected as controls. Thus cells were first transfected to overexpress miRNA-1. To test the 
transport, treatment media of the cells was collected for RT-PCR. This allowed detection of the 
difference in transport of miRNA between the cells in La3+ treated (blocking connexin 
transport) and control (non La3+ treated) medium. Hence, AC16 cells were divided into two 
groups, miRNA-1 transfected and scrambled transfected (transfection control) and both of these 




Figure 2.4 Experiment design for testing Cx43 mediated miRNA transport in AC16 




Cells at 15th passage were seeded at a density of 800,000 cells/well into a 6-well plate and were 
grown in complete DMEM/F-12 media in the incubator (37°C, 5% CO2) for 24 hours. They 
were either transfected with 25 pmol of mirVanaTM miRNA-1 mimic (ThermoFisher, US) or 
25 pmol of LNA-Scramble (ThermoFisher, US) depending on the assigned cell group. 
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LipofectamineTM RNAiMAX (ThermoFisher, US) was used as the transfection agent. First, 9 
µl of Lipofectamine RNAiMAX reagent was diluted in 150 µl of serum free DMEM/F-12 
media in a 0.65 ml Eppendorf tube. Next, 3 µl of miRNA-1 (10 µM) was diluted in 150 µl of 
serum free DMEM/F-12 media in another 0.65 ml Eppendorf tube. Identical protocol was 
carried out for scramble sequence dilution. The diluted Lipofectamine RNAiMAX reagent was 
then mixed with diluted miRNA-1 or scrambled sequence in 1:1 ratio and the mixtures were 
incubated for 5 minutes at room temperature. Then 250 µl of the mixed Lipofectamine 
RNAiMAX and miRNA-1, or Lipofectamine RNAiMAX and scramble mix was added to each 
of the wells of a 6-well plate. The plates were incubated for 28 hours at 37°C, 5% CO2. 
 
2.2.5 Lanthanum treatment Protocol 
For introducing treatment, SILAC media (ThermoFisher, US) was used to restrict further cell 
growth during the treatment phase. For this, the transfecting medium was aspirated out and cells 
in each well were washed with PBS (600 µl/well) twice. For control group, SILAC 
(ThermoFisher, US) with FBS and A/A was added as 800 µl/well whereas for Lanthanum 
treatment group, 2mM La3+ was also added to the SILAC (A complete supplementation recipe 
is listed in Table 2). The cells were incubated for 24 hours at 37°C, 5% CO2, after which media 
for each cell group was collected for RNA extraction and cells were collected for protein 











Table 2. Volume of components forming SILAC used in cell treatment 
Components SILAC for control treatment 
(µl) 
SILAC with La3+ 
(µl) 
FBS 800  800  
A/A 50 50  
La3+ 5 µl in RNase free water 2 mM in 5µl RNase free water 
SILAC 4145 4145 
Total 5000 5000 
 
 
2.2.6 RNA extraction from cell media 
The filter column method was used to extract RNA from the media. First, quizol was added to 
the media (1 : 5; media : quizol) and the samples were briefly vortexed and incubated at room 
temperature for 5 minutes. Chloroform was then added to the sample (1:1; media : Chloroform). 
The samples were vortexed again and incubated for 3 minutes at room temperature before 
centrifuging at 12,000g at 4°C for 15 minutes. The resulting aqueous phase which contains 
RNA, was transferred to a new Eppendorf tube and 100% ethanol was added to precipitate 
RNA in the solution. The precipitated solution was immediately transferred into the column 
filter and centrifuged at 8000g for 15 seconds at room temperature. The flow-through was 
discarded and each column filter was washed with 700 µl of RWT buffer by 15 seconds 
centrifugation at 8000g in room temperature. This was followed by two times wash with 500 
µl RPE buffer with same centrifugation as RWT. The columns were then transferred into a new 
tube and dried, again by 8000g centrifugation for 1 minute. Finally, the RNA was recovered by 
adding 40 µl of RNAase free water to the columns. The columns were incubated at room 
temperature for 2 minutes and then centrifuged at 8000g for 1 minute at room temperature. The 
purity of the obtained RNA was measured as described in section 2.1.4.1 and the RNA was 
stored at -80°C. 
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2.2.7 microRNA Reverse Transcription 
The RNA samples obtained from cell media were transcribed to cDNA as in gene RT-PCR, 
because the stable structure of cDNA allows for more specific targeting of miRNAs. The RNA 
samples were thawed on ice and their concentrations were measured. The samples were then 
diluted in RNase-free water to obtain 20 ng in 5 µl. The RT master mix was then prepared as 
per TaqMan ® RT kit protocol (components listed in table 3) and mixed with the primers of 
miRNAs of interest (miRNA-1, miRNA-16 and miRNA-U6) in 70 : 30 ratio of RT master mix 
: primer. In the interconnected thermocycler tubes, 10 µl of  the combined RT master mix and 
primer was added to 5 uL of the 20 ng RNA. The tubes were briefly spun down in the mini-
centrifuge to ensure mixing of all components and run in the thermocycler. The thermocycler 
run consisted of the following four steps: 16oC for 30 minutes, 42oC for 30 minutes, 85oC for 5 
minutes and 4oC on an infinite hold. cDNA samples were stored in -20oC freezer or immediately 
used in PCR. 
 
Table 3 Volume of RT master mix components required for 1 reaction 
Components 1 reaction (µl) 
100mM dNTPS 0.15 
Multiscribe Reverse Transcriptase 1 
10x Reverse Transcription Buffer 1.5 
RNase Inhibitor 0.19 
Nuclease-free water 4.16 
Total volume 7 
 
2.2.8 miRNA PCR: 
A PCR master mix was made of Takara PCR Premix, ROX dye and RNAse free water with 
specific volume per reaction in table 4. For each sample, in a 96-well plate PCR reaction is 
carried out in triplicate to increase the validity of the results. The plate was sealed and briefly 
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spun down to ensure mixing of all components. StepOne Plus real time PCR machine was used 
to run the samples. The run consisted of three different steps: step one is 30 seconds at 95oC, 
step two is 40 cycles of 5 seconds at 95oC and 30 seconds at 60oC and step three is an infinite 
hold at 4oC. 
 
Table 4. Volume of master mix component for PCR on miRNA samples 
 
 
2.3 Cx43 protein western blot 
To test if Cx43 proteins were adequately expressed in WT oocytes and AC-16 cells, western 
blot was performed. Protein was first extracted from the samples, and protein concentration for 
each sample was determined using Bradford assy. For negative control, protein extracted form 
native oocytes was used. A western blot was performed and observed band size for each sample 




2.3.1 Protein extraction: 
Oocytes: 
The oocytes were collected after electrophysiology for western blot. The protein extraction 
process was performed on ice. The oocytes were homogenised in lysis buffer (Appendix 2, 
Table 7), used as 10µl/per oocyte. The homogenate was then centrifuged for 10 minutes at 
Components For 1 reaction (µL) For triplicate reaction 
(+20% extra) (µL) 
PCR premix (Taqman or 
SYBR) 
6.3 22.5 
20X TM primer 0.5 1.8 
RT product of each sample 1.0 3.6 
RNAse free water 4.8 17.1 
ROX dye (50X dilution) 0.9 3.3 
Total 13.4 48.3 
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10,000g at 4°C and this resulted in formation of the three following phases, debris pellet at the 
bottom, protein containing colourless-liquid phase in the middle and lipids located at the top. 
The colourless liquid layer was extracted and to increase purity of the extracted protein, 
centrifugation step was repeated. The protein lysate was subsequently frozen at -80°C. 
 
AC16 cells: 
To lyse AC16 cells, complete radioimmunoprecipitation assay buffer (RIPA buffer) was used. 
Protease inhibitor (25X) was added just before use. Complete RIPA was added to the cells in 
quantity of 150 µl per well of a 6-well plate. The cells were then transferred on ice and were 
repeatedly passaged through a 24 mm gauge needle to further lyse the cells. Lysed cells were 
incubated on ice for 20 minutes. They were then transferred into a 1.5ml Eppendorf tubes and 
were centrifuged at 16,000g at 4°C for 20 minutes. The colourless supernatant, which contains 
protein was collected and stored and at -80°C. 
 
2.3.2 Bradford assay 
The Quick Start TM Bradford protein assay (Bio-Rad, US) was used and the supplier’s protocol 
for a 96-well plate Bradford assay was followed. In brief, a 200 µg/µl bovine serum albumin 
(BSA) protein sample was aliquoted to prepare a standard curve for determining sample protein 
concentration. The standard was developed by step-wise protein dilution of BSA as outlined in 
the BioRad Microplate Standard Assay (Bio-Rad Laboratories Inc. protocol). Samples were 
prepared in 1 : 1000 dilution ratio of sample protein : Bradford reagent and vortexed to allow 
binding of Coomassie Blue Dye present in the reagent with the proteins. For each sample, 100 
µl was pipetted in triplicate in a 96-well plate and the absorbance of samples and for standard 
was read in Multimode Synergy Reader (BioTek ®) at 595 nm wavelength. A standard curve 
was plotted with the optical density plotted (on Y-Axis) for each standard concentration (X-
Axis). The protein concentration of the each sample was calculated from the equation derived 
from standard curve. 
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E.g. Y = 0.028x + 0.010 
Rearranged to x = (Y-0.010)/0.028 
[ Y= optical density; x=concentration] 
 
2.3.3 Sample preparation 
After determining the protein concentration, the samples were diluted with dH2O and 
appropriate amount of loading buffer to the desired concentration and were then denatured by 
incubation at 95 oC for 4 minutes. The samples were then transferred on ice to be used in the 
gel electrophoresis stage. 
 
2.3.4 Gel electrophoresis 
A 10% resolving gel and 4% stacking gel was used to run the samples (components forming 
both gels are listed in Appendix 3, Table 9). The eelectrophoresis tank was set together, and the 
chambers were filled with SDS running buffer. The ladder was added to the first well (4 µl ) to 
estimate the size of the protein. Samples were then loaded in other wells, initially 20 µg of 
sample was used but this was optimised to 40 µg loading of samples to obtain easily 
distinguishable protein bands later in the western blot. The gel was run at 80V for 30 minutes 
to allow for proteins to run through the stacking gel and then the voltage was increased to 150V 
and the gel was run for another 1 to 2 hours - until the protein samples reached the bottom of 
the gel. The SDS, being an anionic detergent, denatures protein resulting in the negative charge 
of the protein being proportional to the protein length. Hence, the protein movement through 
the gel allows for size based separation. A band was expected to be detected at ~43kDa for 
Cx43 and ~41kDa for GAPDH protein. 
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2.3.5 Gel transfer 
The proteins from the gel were transferred on the PVDF membrane by wet transfer 
electrophoretic elution method. The transfer sandwich was prepared with two sponges and four 
filter paper pre-soaked in transfer buffer. The black side of the plastic cassette was placed at 
the bottom, first a sponge and then two filter paper were stacked on which the gel was placed. 
Then the PVDF membrane activated in methanol for 15 seconds and then briefly immersed in 
transfer buffer, before being placed on top of the gel. The second set of two filter paper and 
then sponge were stacked on top of the PVDF membrane and transfer sandwich was closed to 
be loaded into the transfer box. The transfer was set at a constant voltage of 110V and run for 
one hour 90 minutes. 
 
2.3.6 Staining 
The PVDF membrane was washed three times (5 minute each) in TBS. Membrane was then 
incubated for 90 minutes at room temperature in blocking buffer consisting of 5% Bovine 
Serum Albumin dissolved in tris buffered saline. This was done to conceal non-specific binding 
sites on the membrane. The TBS washes were repeated and the membrane was then incubated 
in cold room for 16 hours in primary antibody, rabbit anti-Cx43 (abcam, USA; Cat. No. 
ab63851) diluted at 1:1000 ratio in 0.1% BSA. Following this, the membrane was washed four 
times in TTBS buffer to remove any protein unattached to the primary antibody. The secondary 
antibody, goat anti-rabbit IgG HRP was then added to the membrane and incubated at room 
temperature for 2 hours. The membrane was once again washed three times for 5 minutes in 
TTBS. ECl (enhanced chemiluminescence) substrate (ThermoFisher, US) was added to the 
membrane in 1:1 ratio and incubated for 5 minutes, following which the membrane was placed 
between plastic sheet hyperfilm cassette to be imaged by Chemiluminescnee PXi Touch 
imaging system (Syngene, UK). 
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As the band sizes for Cx43 and GAPDH are similar, the membrane was stripped following 
Cx43 imaging to proceed towards GAPDH staining. Membrane was first incubated in mild 
stripping buffer (Appendix 3, Table 8) for 2 hours to strip the Cx43 antibodies and then imaged 
again to see if the stripping was successful (lack of visible bands). If not, the membrane was 
incubated in stripping buffer again for another 30 minutes and then imaged. To stain for 
GAPDH, the steps from membrane blocking were carried out again and rabbit anti-GAPDH 
antibody (GeneTex US, Cat.No. GT239)  was used. 
 
2.4 Data analysis 
PCR results 
The CT values represent the number of cycles required for florescent signal to reach threshold. 
A high CT value represents a lower miRNA or gene expression. The triplicate CT values for 
each sample are averaged. Further, to account for variability between groups, CT values for each 
sample were normalised to the CT values obtained for the endogenous control in the same 
sample i.e. U6 values for miRNA-PCR and 18S values for gene-PCR. The difference in CT 
value (DCT) were calculated using 2DCT equation. To represent the increase in DCT as increase 






Protein in each sample visualised on PVDF membrane, was quantified using Image J. Each 
individual band that represented the protein of interest was selected using a constant area for 
the region of interest (ROI). The mean grey value within the ROI was measured for Cx43 
expression and these values were normalised to the mean grey value of loading control, 
GAPDH, of the same sample. This was done for western blot data for proteins detected for WT 
oocytes, native oocytes and AC-16 cells. An unpaired t-test was used to determine if significant 




Statistical analysis for results of all experiment was performed in the GraphPad Prism 7.0 
Software (GraphPad Software Inc, US). For experiments, where the total number of treatments 
was three, ANOVA was done. For the experiments with total number of treatment group was 
less than three, t-test was performed. A p-value <0.05 was considered statistically significant 





The aim of this project was to elucidate a novel role of human Cx43 in the intercellular transport 
of miRNA. The objectives were first, using oocytes, to find whether Cx43 mediated transport 
occurs in the absence of vesicular transport pathways that oocytes do not possess, and then to 
investigate the possibility of miRNA transport through Cx43 channels in adult human 
cardiomyocytes. 
 
In the following pages, first presented are data useful for constructing a suitable single cell 
model of Xenopus laevis oocytes in which miRNA transport via human Cx43 could be tested 
without hindrance from vesicular transport pathways that are seen in cardiomyocytes. 
Quantitative data for endogenous connexin expression in Xenopus laevis oocytes and set up in 
which transport via exogenously expressed human Cx43 in Xenopus laevis oocytes can be 
controlled. 
 
In the later pages of this chapter, the results for miRNA transport in cardiomyocytes are 










3.1 Xenopus laevis oocytes: 
3.1.1 Endogenous Xenopus connexin expression 
Quantitative RT-PCR was performed on RNA extracted from the native Xenopus oocytes to 
measure the expression of endogenous Cx43 (Xenopus Cx43). Three separate experiments on 
oocytes, each from a different frog, were performed. In each experiment, oocyte RNA used in 
RT-PCR was pooled from 3 oocytes of the same Xenopus laevis frog. As previously mentioned, 
Cx38 gene is well expressed in Xenopus laevis oocytes, and its expression was quantified for 
comparison with Xenopus Cx43 expression. The gene RT-PCR results show that, compared 
with the 0.6728 (±0.359) mean for the expression of Xenopus Cx38 (n=9, N=3) gene, the mean 
of the Xenopus Cx43 gene expression of 0.00029 (±0.00049; n=9, N=3) was significantly lower 
in the oocytes, (p < 0.05) (Figure 3.1). The expression of human Cx43 (n=3) gene was 
quantified as the negative control for this experiment and as expected, its expression was not 
detected (Figure 3.1). 
 
 
Figure 3.1 Expression of endogenous connexin genes in native Xenopus laevis oocytes.  
RT-PCR analysis data with CT values normalised to 18S control gene and plotted as 
quantitative measure of connexin gene expression (n= 9, N=3 for all connexin genes). Data are 
presented as mean ±SEM. *p < 0.05, one-way ANOVA with Tukey’s post hoc.  
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3.1.2 Assessment of lanthanum toxicity 
To test the functional properties of Cx43 mediated transport in oocytes, it was first necessary 
to optimise the connexin activating and blocking solutions to ensure adequate oocyte survival. 
The oocytes were bathed in Ca2+ free solution and La3+ solutions and their survival was 
quantified by counting the number of living oocytes over time under the dissecting microscope. 
The images in figure 2.2 were used as the guideline for identifying dead oocytes from the cell 
survival count. The commonly used Xenopus laevis oocyte culturing solution, culOri was used 
as the positive control and oocytes incubated in dH2O was used as the negative control 
 
Over the first 48 hours, 100% of the oocytes survived in culOri solution (Figure 3.2) but by 72 
hours the oocyte survival had decreased to 64% in the culOri solution (Figure 3.2). However, 
at each time point, the proportion of oocyte surviving is highest for oocytes incubated in culOri. 
As expected, the oocytes incubated in dH2O, that served as the negative control, were least 
viable, dying instantly– data not shown in graph. 
 
To activate connexins, CaCl2 was eliminated from culOri and this modified solution is labelled 
as Ca2+ free solution. There is no significant difference in percentage of survival for oocytes 
incubated in culORi and in Ca2+ free solution, from the start (0 hour) to 72 hours (p > 0.9). At 
the 96 hour time point, the percentage of oocyte surviving in Ca2+ free solution decreased 
significantly to 49% compared to 62%  for the oocytes bathed in culOri (p < 0.05). 
 
To identify a tolerable La3+ dose for oocytes in which cell lysis is minimal, oocyte survival was 
tested at 50µM, 100µM, 500µM and 1000µM La3+. An inverse relationship was observed 
between oocyte survival percentage and La3+ concentration where oocyte survival is decreased 
with increases in La3+ concentration (Figure 3.2). When proportion of  oocytes survival between 
oocytes incubated in varying La3+ concentration and culORi was compared, no significant 
decreases in survival was seen for oocytes bathed in 50µM La3+ between 0 to 72 hours (p > 
0.9).  The significant decrease however was noted for higher La3+ concentration of 100µM, 
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500µM and 1000µM La3+ between 24 to 72 hour time frame (p < 0.0001). Given the lack of 
significant difference between percentage of oocytes surviving in 50µM La3+ and culOri for 0 
to 72 hours, the 50µM La3+ concentration seemed to be a more tolerable La3+ dose for oocytes. 
Thus, 50µM La3+ concentration solution was chosen for blocking connexin mediated current in 
Xenopus laevis oocytes, so the cells are viable throughout the experiment. 
 
 
Figure 3.2 Survival of Xenopus laevis oocytes in connexin activating and blocking 
solutions. All La3+ concentrations were prepared in Ca2+free solution. n= total number of 
oocytes, N=total number of frogs oocytes were extracted from. Data presented as percentage 
mean ±SEM. Two-way ANOVA with Tuckey’s post hoc performed, *p < 0.05, ****p < 0.0001 
represent significant difference in survival of oocytes in culOri versus 100µM, 500µM and 
1000µM La3+ concentrations, #p < 0.05 represent significant difference in survival of oocytes 
in culOri versus Ca2+free and 50µM La3+ concentration.  
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3.1.3 TEVC current recordings 
The two electrode voltage clamp (TEVC) system allows the oocyte to be clamped at a selected 
voltage to adjust the membrane potential and enables recording of the membrane current which 
reflects ion channel activity at that voltage. Here we used TEVC to determine if human Cx43 
that were expressed in oocytes via exogenous mRNA expression, are functional. The whole cell 
current for human Cx43 cRNA injected and control (RNase free water injected) Xenopus laevis 
oocytes was measured. 
 
The oocytes were voltage clamped at -60mV. To see if connexin expressed is functional, a 
connexin specific current was induced by introduction of Ca2+ free solution for 3 minutes. In 
both oocyte groups this was followed by 2 minute long washing with simply oocyte Ringer’s 
solution containing Ca 2+ (Appendix 1, Table 6). The change in current induced by Ca2+ free 
solution was recorded. The specificity of this current to functioning connexin channels was then 
confirmed by inhibiting the current via the application of 50µM La3+ prepared in Ca2+ free 
solution to ensure that, the inhibition of current was an effect of La3+ and not due to Ca2+ in the 
solution. 
 
The representative trace for TEVC recording in figure 3.3A for human Cx43 cRNA injected 
and control oocytes, both show that Ca2+ free solution induced a current which was fully 
diminished on the application of culOri. Furthermore, the application of 50µM La3+ inhibited 
the Ca2+ free induced current in both groups of oocyte, though it did not do so completely. 
The change in current observed on the application of each solution illustrated in figure 3.3A is 
quantified in figure 3.3B. Although there was a higher mean change of Ca2+ free induced current 
in Cx43 cRNA injected oocytes (1.1µA ±0.317µA; n=6, N=3) in comparison to the control 
oocytes (0.764µA±0.11; n=11, N=3), this difference was not significant in a one-way ANOVA 
analysis (p > 0.9). On the application of La3+, there is 50% decrease in current induced by Ca2+ 








Figure 3.3 TEVC current recordings of Xenopus laevis oocyte. A) Representative trace of 
current recorded in single Cx43 cRNA injected and a control (RNase free water injected) 
oocyte. B) Measurement of change in current induced by Ca2+ free solution and subsequent 
inhibition by 50µM La3+ for Cx43 cRNA injected and control oocytes. *p < 0.05, **p<0.01, 
one-way ANOVA. Data are presented as mean ±SEM. (n=5 to 11). 
3.1.4 Expression of Human Cx43 in Xenopous laevis oocytes 
The failure to demonstrate a clear difference in current between the human Cx43– expressing 
oocytes and the controls raises the possibility that the oocytes were failing to express the human 
Cx43 channels. To test this, the expression of the human Cx43 protein was measured.  Western 
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blot analysis was performed on protein extracted from human Cx43 cRNA injected and control 
oocytes (RNase free water injected) to detect human Cx43 expression. Because AC16 cells 
endogenously express Cx43 protein, protein extracted from these cells was used as the positive 
control. For negative control, 20µl of blank (RNAse free water + loading dye) was loaded. 
 
A 43kDa band was seen for AC16 cells and for all samples of both human Cx43 cRNA injected 
(n=5) and control oocytes (n=5) (Figure 3.4 A). As expected, no bands were seen for the 
negative control. 
 
The human Cx43 expression for each sample was quantified and normalised to GAPDH as 
described in Chapter 2, section 2.4, protein analysis. The normalised Cx43 value presented in 
figure 3.4 B, show significantly higher expression of Cx43 protein in human Cx43 cRNA 










Figure 3.4 Oocyte western blots to detect Cx43 expression. A) Each well was loaded with 
40 µg protein extracted from pool of 10 oocytes that belong to the same group. Wells 1 and 2 
represent positive control (Cx43 from AC16 cells). 3, 4, 5, 6 and 7 are protein samples of Cx43 
cRNA injected oocytes. Wells 8, 9, 10, 11 and 12 protein samples extracted from control 
(RNase free water injected oocytes). Well 13 is negative control loaded with blank (20µl RNase 
free water and SDS combined). GAPDH was the loading control. B) Quantification of Cx43 
protein expressed in Cx43 injected (n=5) and control oocytes (n=5), plotted as arbitrary unit 
(A.U) after normalised to GAPDH expression. Each data point represents a mean of three 
technical repeats. *p < 0.05, non-parametric two-tailed unpaired t-test. Mean for the overall 
group is represented as bar graph where the error bars represent SEM. 
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3.2 miRNA transport in cardiomyocytes (AC-16 cells) 
3.2.1 Detection of miRNA via RT-PCR results 
The hypothesis that miRNA transport occurs via Cx43 in AC16 cells was tested by looking at 
the transport of miRNA-1 from the lanthanum treated and non-lanthanum treated cells into the 
cell media (Figure 2.4). To block connexin transport, 2mM La3+ concentration was used as it 
has been shown to block 90% of Cx43 channel activity in rabbit ventricular myocytes (Kondo 
et al., 2000). 
 
The RT-PCR results in figure 3.5 show minimal transport of miRNA-1 into the media from the 
scrambled transfected cell group. The mean for miRNA-1 expression in media was 0.4786 
(±0.253) and 1.27 (±0.438) for control scramble transfected and lanthanum treated scramble 
group respectively. There was no significant difference between the lanthanum treated cells and 
control of the scramble group (Figure 3.5). 
 
The expression of miRNA-1 in media of control miRNA-1 transfected AC16 cells 
(12.11±0.959; n=3) was significantly higher than the control of scramble transfected cells 
(1.27±0.438) (p < 0.0001). However, no significant difference was found after lanthanum 
exposure in miRNA-1 transport in the miRNA-1 transfected cells (figure 3.5). The mean values 
for miRNA-1 expression in media for lanthanum, treated of miRNA-1 transfected cells and 
their control were 12.01 (± 0.354) and 12.11 (±0.960) respectively. 
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Figure 3.5 Transport of miRNA-1 from AC16 cells into the media. The RT-PCR was 
performed on RNA extracted from the cell media of AC16 cells 24 hours after lanthanum or 
control treatment. Each data point on scatter plot represent average of triplicate CT values, 
normalised to U6 and miRNA-16 expression. Errors bars on bar graph represent SEM. ****p 
< 0.001, one-way ANOVA with Sidak’s multiple comparisons test. n=3 for each group.  
 
3.2.2 Quantifying Cx43 expression in AC16 cells 
To confirm that lanthanum was not altering the expression of Cx43 in AC16 cells, western blots 
were performed on AC16 cells treated with 2mM lanthanum for 24 hours and 48 hour and the 
expression of Cx43 was measured. For both, 24 and 48 hour time point, AC16 cells treated with 
SILAC were used as the control. 
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A 43kDa band was detected for all samples of both control and 2mM lanthanum treated group 
(Figure 3.6). There was no significant difference found in the expression of Cx43 protein in 








Figure 3.6 Cx43 expression levels in AC16 western blots for cells treated with 2mM 
Lanthanum. A) Each well was loaded with 40µg of protein sample gathered from cells seeded 
at 800,000 density. 1 and 2 are protein from 24 hour control, 3 and 4 are protein from cells 
treated with 2mM La3+ for 24 hours, 5 and 6 are protein from 48 hour control, 7 and 8 are 
protein from cells treated with 2mM La3+ for 48 hours. B) Quantitative analysis of western 
blot showing Cx43 expression in AC16 control and lanthanum group for 24 hour and 48 hour 
time point. Expression of Cx43 plotted as arbitrary unit (A.U) after normalisation to GAPDH 
expression. n= 3 for each group and each data point on the scatter plot represents an average of 
2 technical repeats. Shapiro-Wilk normality test was done for normalisation and then one-way 
ANOVA was performed. Errors bars on the bar graph represent SEM. 
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3.3 Results Summary 
There are endogenous connexin genes present in Xenopus laevis where expression of 
endogenous Cx38 is significantly higher than endogenous Cx43. Human Cx43 cRNA was 
injected into Xenopus laevis oocytes to build a construct in which human Cx43 mediated 
miRNA transport can be tested. No functional difference was seen between human Cx43 cRNA 
injected and control oocytes when TEVC was used to assess the presence of Cx43 channels. In 
both groups of oocytes, a connexin specific current was induced by incubation in Ca2+free 
solution and was subsequently inhibited by lanthanum. Because of the known expression of 
endogenous Cx38 in Xenopus laevis oocytes, a Ca2+free induced current was expected in the 
control group. However, a higher Ca2+free induced current was expected in the human cRNA 
injected oocytes due to overexpression of Cx43 post cRNA injection and 24 hour incubation. 
 
This lack of functional difference was investigated by quantifying Cx43 expression in human 
Cx43 cRNA and control group by western blot. It was found that Cx43 was significantly highly 
expressed in human cRNA injected oocytes compared with control oocytes. 
 
For the cardiomyocyte model, no significant difference was seen in miRNA transport between 







The role of miRNA in modulating cardiovascular diseases is extensively studied and their 
transport pathways are explored to form miRNA based therapy for CVDs. The currently known 
transport route of miRNAs via membrane–bound vesicles have off-target effects  due to the 
lack of target specificity of these vesicles. Some studies have looked into a connexin protein 
mediated pathway as an alternative to the vesicular transport of miRNAs and as a more specific 
transport via gap junction proteins for miRNA transport between cells cardiac cells. The 
transport of miRNA through the mouse isoform of connexin Cx43 has been demonstrated in 
the HeLa cell line (Zong et al., 2016) and in neonatal rat cardiomyocytes (Lemcke et al., 2017). 
However, to the best of my knowledge this study is the first to test for the transport of miRNAs 
via human Cx43 that predominantly form gap junctions between ventricular cardiomyocytes. 
4.1 Human Cx43 in Xenopous laevis oocytes 
The expression of native connexin Cx38 and Cx43 genes was examined first. Although it is 
well known that the oocytes express Cx38 gene (Ebihara et al., 1989; Haefliger et al., 1992), 
there is minimal information on Cx43 gene expression in Xenopus laevis oocytes (Gimlich et 
al., 1990). The gene RT-PCR data (Figure 3.1) showed that, compared to the expression of 
connexin Cx38 gene, there was only minimal presence of native Cx43 gene in the non-injected 
oocytes (ratio of Cx43:Cx38 = 0.000431034:1). With this background information, experiments 
were then performed to express human Cx43 in the Xemopous oocytes. This was accomplished 
successfully as shown by the western blot data (Figure 3.4).The bands in each sample were 
detected close to 43 kDa as seen in the positive control (Cx43 from AC16 cardiomyocytes) 
lanes, thus confirm the presence of Cx43 in both sample groups.  
 
However, although the gene RT-PCR data, showed virtually no human Cx43 in the native 
oocytes, here the western blot data showed apparent expression of human Cx43 proteins in both 
the human cRNA injected and, to an appreciably and significantly lesser extent (p<0.05), in the 
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control group. The apparent presence of Cx43 in the control group is unlikely to result from 
contamination, as no bands were observed in the negative control (Figure 3.4). One possible 
explanation for the detection of a Cx43 band in control oocytes could be a lack of specificity of 
the Cx43 antibody for human Cx43. The antibody in this study was a polyclonal rabbit anti-
Cx43 antibody. While the use of polyclonal antibodies is advantageous in detecting protein 
expression as they can bind to different epitopes of the protein of interest, it can also have 
disadvantageous, as recognition of multiple epitopes can lead to non-specific binding in 
homogenous proteins (Neil et al., 2005). Therefore, the unexpected detection of Cx43 in control 
oocytes may reflect a lack of antibody specificity with detection of expressed Xenopus Cx43 
protein. It is also possible that Xenopus Cx38 is detected as well. This is supported by findings 
of  (Haefliger et al., 1992) which shows homogeneity between the structure of Cx38 and Cx43 
proteins. 
Also for the western blot experiment, as a control for cRNA injection, it would have been 
interesting to perform a western blot on non-injected oocytes and to investigate Cx43 
expression in these oocytes. In any event, it can be confidently said that cRNA injection worked 
and that human Cx43 proteins were expressed in the Xenopus oocytes.  
 
The mean current in the human cRNA injected oocytes was almost 1.5x greater than that in the 
RNase free water injected control oocytes. However, the difference failed to reach statistical 
significance. This possibly reflects the relatively small sample size (n=6 for the cRNA injected 
group). In addition, there may have simply been insufficient expression of the functional human 
connexin 43. This, together with the expression of endogenous connexins (Cx38 and Cx43) in 
the control and treated oocytes, would limit the magnitude of the differences in current between 
the two experimental groups. In support of this possibility, Ebirah (1996), has shown that the 
expression of Cx38 protein in Xenopus oocytes and the endogenous Cx38 in Xenopus laeivis 
oocytes induces whole cell current upon application of Ca2+ free solution. Due to the lack of 
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significant functional difference in the present human Cx43 expressing oocytes, the hypothesis 
of miRNA transport via human Cx43 in Xenopus oocyte model could not be tested. 
 
However, in this study it was established that connexins in oocytes can be successfully activated 
by Ca2+ free solutions and inhibited to a significant extent by concentrations of lanthanum that 
avoid toxicity. The highest viability of oocytes in Ca2+ free solution is seen in the first 48 hours 
(Figure 3.2). The results further support the use of 50µM La3+ which is tolerated by the cells. 
As the TEVC recordings show, 50µM La3 blocked the activity of connexins in oocytes 
significantly. Thus, these findings demonstrate that transport via connexins can be examined 
by testing in the first 48 hours of incubation. This avoids hindrance in quantifying Cx43 
mediated transport due to deterioration of the oocyte membrane. 
4.2 Modifications for Xenopus oocyte model for subsequent 
experimental studies. 
The results reported here illustrate the need to refine the Xenopus oocyte model to obtain more 
precise data. There is a need to reduce endogenous connexin expression in oocytes before using 
them to test miRNA transport. It is already established that ion transport via all connexins in 
general is Ca2+ and La3+ sensitive. Thus, to test the functionality of exogenously expressed 
human Cx43, the Xenopus oocyte must be modified to have low endogenous connexin activity. 
The Xenopus Cx38 and Xenopus Cx43 knockdown oocyte model would allow adequate 
comparison of the Ca2+ free current induced by human Cx43. Bao et al., (2004)  studies have 
shown knockdown of endogenous connexin has enabled concrete functional recordings of 
exogenous connexin. 
It is also possible that the results were confounded by the quality of the oocytes as the oocytes 
were extracted from different frogs each week. Though visually uniform oocytes within stage 
V-VI were selected, the ability of the oocytes to transcribe exogenously expressed human Cx43 
cRNA could vary for oocytes extracted from different frogs. 
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4.3 miRNA transport in cardiomyocytes 
The miRNA transfected group of cells secreted miRNA into the medium. However, this 
secretion was not blocked by 2 mM lanthanum (Figure 3.5). Lemeke et al., (2017) found using 
a different experimental approach in isolated neonatal cardiomyocytes, found a 50% decrease 
of miRNA mimic transport following Cx43 knockdown. Other than the fact that (Lemcke et 
al., 2017) tested mRNA transport in neonatal rat cardiomyocytes whereas AC16 cells are 
representative of adult human cardiomyocytes, these contrasting results could be explained as 
a consequence of the different methodology used to test Cx43 mediated miRNA transport. First, 
in this study the transport of miRNA was tested from the cells into the media whereas Lemeke 
et al tested the transport of miRNA between the cells using 3D-FRAP microscopy. Their model 
included a Cx43 knockdown whereas, in this project connexin blocker lanthanum (2mM) was 
used to control transport via Cx43. The transport function of connexin is hindered by lanthanum 
that blocks the channel pore via a particle-receptor binding mechanism (Morley et al., 1996).  
As the result illustrated in figure 3.6 show, the 2mM lanthanum concentration used here to 
block connexin did not affect the expression of Cx43 protein itself. Based on the demonstration 
that 50µM lanthanum concentration in the oocytes inhibited 50% of connexin channel activity, 
the use of 2mM lanthanum in cardiomyocytes should have blocked the Cx43 channel activity 
sufficiently.  
4.4 Possible reasons for lack of miRNA transport inhibition by 
lanthanum in cardiomyocytes 
When accessing the data in figure 3.6 it is important to recall the presence of vesicular transport 
pathways in cardiomyocytes. The transport of exosomes and microvesicles was not blocked in 
AC16 cell treatment groups. There is evidence that the half-life of the Cx43 protein in the 
cardiomyocytes incubated  in vitro  is within 1 hour to 5 hours (Laird et al., 1991). This suggests 
that during 24 hour incubation other pathways must account for a significant amount of the 
miRNA transported into the media. This offers the best explanation for the failure of lanthanum 
to block the movement of miRNA-1 from cardiomyocytes.  
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A less likely possibility that might have contributed to the lack of effect of lanthanum would 
be cell damage. The choice of 2 mM La3+ was based on the work of  who exposed cultured 
myocardial cells in vitro 2 mM La3+ for 5 minutes (Kondo et al., 2000). This is a much shorter 
exposure than the 24 hours used here. If the current study were extended, the effects of different 
concentrations of lanthanum on AC16 cardiomyocytes would be examined.  
4.5 Conclusion 
Given the gaps in the experimental design of this study, the hypothesis of Cx43 mediated 
miRNA transport could not be established with the present results. Further experiments must 
be carried out where transport via human connexin is tested in the absence of vesicular transport 
pathways as well as other proteins of the connexin family. The confound of endogenous 
connexins present in native oocytes suggest a new proposed model for testing Cx43 mediated 
miRNA transport in Xenopus oocyte is a knockdown of Xenopus Cx38 and possibily Xenopus 
Cx43. 
4.6 Future Directions 
For both models, it would be wise to explore other known connexin channel blockers such as 
heptanol, rather than relying solely on lanthanum. 
Xenopus oocyte model  
Using an endogenous connexin knockdown model of Xenopus oocyte. The miRNA transport 
via human Cx43 can then be tested by testing the transport of miRNA-1, as this is a 
predominantly found miRNA in the heart and is not expressed in Xenopus oocytes. The mimic 
miRNA-1 can be injected in the oocytes and the bath solution can be collected for RT-PCR 
analysis to test the transport of miRNAs (see appendix 5, figure 4.1).  
AC16 Cardiomyocytes  
As the transport was tested from AC16 cells into the extracellular fluid, the methodology of 
this experiment tested transport through connexin 43 formed hemichannels. The junctions 
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between cardiomyocytes are formed by two hemichannels combined to form a gap junction. To 
account for variance in conductance of gap junctions and hemichannels, experiments should be 
performed where transport of miRNA is tested via gap junctions using fluorescence microscopy 
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Table 5. Solution used for oocyte survival test. The 50 µM, 100 µM, 500 µM and 1000 µM 




























 CulOri  
(mM) 
Ca2+ free  
(mM) 
NaCl 90 90 
KCl 1 1 
CaCl 2 - 
LaCl3 - - 
HEPES 5 5 
Na+ Pyruvate 2.5 2.5 
Penicillin 0.06 0.06 
Streptomycin 0.02 0.02 
EGTA 1 1 
pH 7.4 7.4 
 CulOri  
(mM) 
Ca2+ free  
(mM) 
0.05mM La3+ 
NaCl 90 90 90 
KCl 1 1 1 
CaCl    
LaCl3   0.05 
HEPES 5 5 5 
EGTA  1 1 
pH 7.4 7.4 7.4 
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Appendix 2 
Table 7. Composition of lysis buffer used for oocyte homogenisation. To extract proteins 
from oocytes, 10µl lysis buffer was used per oocyte. 
 
Component Amount 
HEPES 10 mM 
NaCl 83 mM 
MgCl2 1 mM 
Triton X-100 1 % 






Table 8: Reagents prepared for Western Blot 
 
Regent  Composition 
Upper Tris (1.5M Tris HCl pH 6.8) § 18.117g Tris (hydoxymethyl) 
§ 90ml dH2O 
§ Adjust pH to 6.8 with 6M HCl 
Lower Tris (1.5M Tris HCl pH 8.8) § 22.59g Tris 
§ 90ml dH2O 
§ Adjust pH yo 8.8 with 6M HCl 
§ Make final volume 100ml with 
dH2O 
10% SDS § 10g sodiumdodecyl sulphate 
§ 80ml dH2O 
§ Make final volume 100ml with 
dH2O 
50% Glycerol § 50ml glycerol 
§ Make final volume 100ml with 
dH2O 
Loading Buffer (2X) § 4.165ml Upper Tris 
§ 10ml 20% SDS 
§ 20ml 50% glycerol 
§ 5ml mercaptoethanol (14.3M) 
§ 500µl EDTA (200mM) 
§ 10.38ml dH2O 
 
Running Buffer (10x concentrate) § 60g Tris base 
§ 288g glycine 
§ 20g SDS (wear mask) 
§ Make up to 2L with dH2O 
Transfer buffer § 7.57g Tris base 
§ 36g Glycine 
§ 500ml Methanol 
§ Make to 2.4L with dH2O and adjust 
pH to 8.3 with NaOH and HCl 
§ Make final volume 2.5L with dH2O 
TBS (10x concentrate) § 80g NaCl 
§ 2.0g KCl 
§ 30g Tris base 
§ Adjust pH to 7.4 with concentration 
HCl 
§ Make final volume 1L with dH2O 
TTBS (0.05%) § 400ml TBS (1x) 
§ 200µl Tween20 
Stripping Buffer § 15g glycine  
§ 1g SDS 
§ 10ml Tween20 
§ Adjust pH to 2.2 with conc. HCL 
§ Make final volume 1L with dH2O 
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Table 9. Component and ratios for making resolving and stacking gels used in 
electrophoresis stage of western blot. 
 
Resolving Gel 
10% 1 Gel (µL) 
dH2O  3150  
Lower Tris (pH 8.8) 2000 
10% SDS 80  
30% AA:MBA 2665  
10% APS (Ammonium Persulphate) 80 
TEMED  8  
Total 8000  
 
Stacking Gel 
 1 Gel (µL) 
dH2O 2100 
Upper-Tris 875 
10% SDS 35 
30% AA:MBA 466 










Primers used for gene Rt-PCR to detect endogenous connexin expression in Xenopus laevis 
oocytes. 


































Figure 4.1 A new experimental design for testing miRNA transport via human Cx43 in 
Xenopus oocytes based on findings of the current study. Cx38 short interfering RNA 
(siRNA) would ensure knockdown of endogenous Cx38 in Xenopus oocytes and will thus 
reduce the interference from endogenous connexin when testing the transport via human Cx43. 
Group A oocytes, as in Ca2+ free solution, will have open connexin channels whereas connexin 
channels in group B oocytes will be blocked due to the presence of  La3+. Comparative RT-
PCR analysis of miRNA-1 detected in the bath solution of group A (Cx43 active) and group B 
(Cx43 blocked) in oocytes will enable understanding of whether Cx43 has a role in miRNA 
transport. 
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